Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia

Inclusion Criteria: * Male and female, 18-75 years old * Patients previously diagnosed with novel coronavirus pneumonia: the course of illness is no more than 14 days; if the course of the disease was more than 14 days, patient meets one of the following conditions can also be included in the group: (1) No apparent absorption or progression of chest radiograph was observed within 7 days; (2) respiratory symptoms (chest tightness, or cough, or breathing difficulties); (3) Test for viral nucleic acid positive within 3 days. * informed consent should be signed by the participate or an authorized agent * Agree to clinical samples collection * Female or male subjects of childbearing age agree to take effective contraceptive measures within 3 months of the last oral medication to ensure that female or male partners of childbearing age do not become pregnant Exclusion Criteria: * Severe vomiting or difficulty ingesting medication * Woman who are pregnant or during lactation * Patients received lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody specific antiviral drugs three days before enrollment * Cases of respiratory failure requiring mechanical ventilation * Shock * Combined with other organ failure and requires ICU care * Clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission